现代医药卫生Issue(4)：509-511,3.DOI:10.3969/j.issn.1009-5519.2016.04.011
舒利迭/信必可联合噻托溴铵治疗中重度COPD稳定期临床疗效观察
Observation on clinical efficacy of seretide and symbicort combined with tiotropium bromide in treating stable stage of moderate to severe COPD
郭海全 1周向东1
作者信息
- 1. 重庆医科大学附属第二医院呼吸科，重庆400005
- 折叠
摘要
Abstract
Objective To investigate the clinical efficacy of seretide and fomoterol powder for inhalation (symbicort) combined with tiotropium bromide in treating the stable stage of moderate to severe COPD. Methods A total of 60 cases of mod-erate to severe COPD treated in our hospital from January to December 2014 were randomly divided into the group A ,B and C,20 cases in each group. The group A was treated by symbicort combined with tiotropium bromide;the group B by seretide combined with tiotropium bromide;the group C by tiotropium bromide. The treatment course was 6 months. The George respiratory disease questionnaire(SGRQ) score before treatment,6 min walking distance(6-MWD),pulmonary function indexes and exacerbation at-tack times were measured in 3 groups. Results The living quality,6-MWD and pulmonary function after treatment in 3 groups were improved,moreover the combined medication was superior to simple medication,the acute exacerbation times in the group A was decreased compared with the group B,the difference was statistically significant(P<0.05). Conclusion The combined medi-cation is the optimal selection scheme for the stable stage of moderate to severe COPD. The symbicort combined tiotropium bro-mide group can significantly reduce the frequency of acute attack than the seretide combined tiotropium bromide group.关键词
沙丁胺醇/类似物和衍生物/支气管扩张药/治疗应用/肺疾病,阻塞性/药物疗法/慢性病Key words
Albuterol/analogs&derivatives/Bronchodilator agents/therapeutic use/Lung diseases,obstructive/drug therapy/Chronic disease引用本文复制引用
郭海全,周向东..舒利迭/信必可联合噻托溴铵治疗中重度COPD稳定期临床疗效观察[J].现代医药卫生,2016,(4):509-511,3.
